CHMP issues positive recommendation for approval of lecanemab in the EU November 14, 2024 17:01 Regulatory Read more
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 – March 2025). Sales now expected to reach JPY 42.5 billion November 8, 2024 05:00 Regulatory Read more
BrainTransporter™ dramatically improves antibody delivery to the brain November 6, 2024 15:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s third quarter report for July – September 2024 on November 14 at 9.30 a.m. CET November 6, 2024 08:30 Non Regulatory Read more
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US November 1, 2024 00:30 Regulatory Read more
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile October 31, 2024 08:30 Non Regulatory Read more
Leqembi® revenue totaled JPY 10 billion in the third quarter 2024 October 30, 2024 11:45 Regulatory Read more
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer’s Disease October 30, 2024 08:30 Non Regulatory Read more
Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD October 24, 2024 08:00 Non Regulatory Read more
Eisai will request reconsideration of initial decision for lecanemab in Australia October 17, 2024 01:30 Non Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of September 30, 2024 September 30, 2024 18:30 Regulatory Read more
Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology August 27, 2024 08:00 Non Regulatory Read more
Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain August 22, 2024 11:05 Regulatory Read more
Regarding rumors of an imminent approval of lecanemab in Great Britain August 22, 2024 08:34 Regulatory Read more
Invitation to presentation of BioArctic’s second quarter report for April – June 2024 on August 29 at 9.30 a.m. CET August 19, 2024 08:30 Non Regulatory Read more
Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates August 14, 2024 01:00 Non Regulatory Read more
Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024 August 1, 2024 12:45 Regulatory Read more
Long-term lecanemab data show increased patient benefit with maintained safety profile July 30, 2024 23:00 Regulatory Read more
Eisai will seek re-examination of CHMP opinion för lecanemab July 26, 2024 13:15 Regulatory Read more
Long-term treatment data for lecanemab to be presented at AAIC 2024 July 23, 2024 08:00 Non Regulatory Read more
Leqembi approved for the treatment of Alzheimer’s disease in Israel July 12, 2024 01:30 Regulatory Read more
Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong July 11, 2024 01:30 Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of June 28, 2024 June 28, 2024 18:30 Regulatory Read more
FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s Disease June 10, 2024 01:30 Regulatory Read more
Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea May 24, 2024 12:55 Regulatory Read more
Bulletin from the Annual General Meeting in BioArctic AB (publ) May 22, 2024 18:00 Regulatory Read more
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025) May 15, 2024 05:45 Regulatory Read more
Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing May 15, 2024 01:30 Regulatory Read more
Invitation to presentation of BioArctic’s first quarter report for January – March 2024 on May 17 at 9:30 a.m. CET May 7, 2024 08:30 Non Regulatory Read more
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024 April 24, 2024 12:45 Regulatory Read more
BioArctic and Eisai sign research evaluation agreement regarding BAN2802 April 20, 2024 09:40 Regulatory Read more
The Nomination Committee’s proposal for the election of Board members and Chairperson of the Board in BioArctic AB April 16, 2024 15:00 Non Regulatory Read more
BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm April 10, 2024 08:00 Non Regulatory Read more
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed April 1, 2024 01:40 Regulatory Read more
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons March 22, 2024 12:30 Regulatory Read more
Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease March 19, 2024 08:00 Non Regulatory Read more
New data on lecanemab presented at the 2024 AD/PD™ congress March 11, 2024 08:00 Non Regulatory Read more
BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference March 7, 2024 06:30 Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of February 29, 2024 February 29, 2024 18:30 Regulatory Read more
Latest data on lecanemab to be presented at the 2024 AD/PD™ congress February 29, 2024 08:00 Non Regulatory Read more
BioArctic’s CEO Gunilla Osswald Winner of The Arthur D. Little Nordic Life Science Award February 22, 2024 08:00 Non Regulatory Read more
Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023 February 6, 2024 04:36 Regulatory Read more
Invitation to presentation of BioArctic’s fourth quarter report for October – December 2023 on February 14 at 9.30 a.m. CET February 5, 2024 08:30 Non Regulatory Read more
The European Medicines Agency’s Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab January 11, 2024 07:00 Regulatory Read more
Leqembi® approved for the treatment of Alzheimer’s disease in China January 9, 2024 09:30 Regulatory Read more
